In addition, increased expression of CB1 and/or CB2 has been noted in human mantle cell lymphoma [80, 81], breast cancer [79], acute myeloid leukaemia [93], hepatocellular carcinoma, and prostate cancer cell lines; however, the levels of both receptors were similar in malignant and nonmalignant human astroglial cancer cells [94] and in malignant and nonmalignant nonmelanoma skin cancer cells [70]. Here, CNR1 is linked to hepatocellular carcinoma.